Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

Trastuzumab deruxtecan is approved for HR-positive, HER2-low/ultralow metastatic breast cancer post-endocrine therapy, based on DESTINY-Breast06 trial results. The trial showed a 36% reduction in ...

Liquid biopsy of circulating tumor DNA (ctDNA) is an "efficient" way to monitor resistance to trastuzumab (Herceptin, Genentech) and spot emerging resistance mechanisms in metastatic human epidermal ...

A regulatory decision is expected during the first quarter of 2025. The Food and Drug Administration has accepted for Priority Review the supplemental Biologics License Application (sBLA) for ...

Patients treated with trastuzumab deruxtecan + pertuzumab had a statistically significant and clinically meaningful improvement in PFS compared with standard of care. Topline results were announced ...

– Combination regimen is approved for use in the second-line treatment setting and beyond – “Historically, patients with HER2-positive metastatic colorectal cancer who have progressed following ...

Literature and guidelines often cite cardiotoxicity rates of 15-20% associated with trastuzumab in patients with HER2-positive breast cancer, primarily on the basis of early trials. A closer look at ...

Based on DESTINY-Breast06 Phase III trial results which showed ENHERTU demonstrated superiority vs. chemotherapy with a median progression-free survival of more than one year Approval brings ...

Herein, we present a case of HR-negative, HER2-positive metastatic breast cancer (mBC) refractory to numerous lines of therapy. Ultimately, biopsy of a metastatic lesion demonstrated a PI3KCA mutation ...